Advanced Defence Gum Treatment
Advanced Defence Gum Treatment is a twice-daily mouthwash clinically proven to treat gum disease as an adjunct to mechanical cleaning and to offer an alternative to chlorhexidine based remedies.
It's formulated with unique LAE (Ethyl Lauroyl Arginate) technology that forms a physical coating on the pellicle to prevent bacteria attaching, and so interrupts biofilm formation. When used after brushing, it treats gum disease as shown by the reduction of bleeding by 50.9% (p<0.001) in only 4 weeks.1
In addition, Advanced Defence Gum Treatment is designed to not cause staining.2
Advanced Defence Gum Treatment is part of the LISTERINE® Advanced Defence range from Johnson & Johnson, a scientifically proven adjunct to your professional treatment.
Designed to help you treat and/or prevent specific oral care conditions, this range also includes LISTERINE® Advanced Defence Sensitive and LISTERINE® Advanced Defence Cavity Guard.
With this range of expert daily mouthwashes, Johnson & Johnson is looking forward to working more closely with dental professionals to help deliver advanced treatment outcomes for patients, for expert care when you’re not there.
For more information on LISTERINE® Advanced Defence, please visit www.dentistry.co.uk/listerine or call 0800 328 0750.
References:
1. Bleeding Index Reduction DOF 1 – 2013 (LAEBBA0001), 50.9% Reduction in whole-mouth mean Bleeding Index at 4 weeks
2. DOF 2-2013 (UNKPLT0006)
About the author
Related Posts
Comments
By accepting you will be accessing a service provided by a third-party external to https://www.gdpuk.com/
GDPUK Ltd announces sale of intellectual property to leading publisher Cogora Group
GDPUK Ltd today announces the sale of its intellectual property assets to Cogora Group, one of the UK's leading publishers of healthcare brands, events and educational platforms.
The decision to sell GDPUK’s intellectual property forms part of a considered transition to ensure the long‑term stewardship and development of the brand and associated assets. Cogora brings a wealth of experience and expertise to support the continued evolution of the dentistry brand within its wide portfolio of market-leading healthcare publications. Its award-winning titles include Pulse, a long‑standing and widely recognised source of political news and clinical education for GPs, Nursing in Practice, Management in Practice, The Pharmacist, Pulse PCN and Healthcare Leader, as well as two secondary care publications – Hospital Healthcare Europe and Hospital Pharmacy Europe. The purchase will cement Cogora as the biggest publisher of primary care titles in the UK and allow it to bring its expertise in providing news, analysis, opinion and groundbreaking stories to GDPUK, as well as continue giving dentists and dental staff a voice through its website.
“After careful consideration, we believe that Cogora is well positioned to take GDPUK’s intellectual property forward,” said Tony Jacobs, founder, editor and publisher of GDPUK.com . “This transaction provides continuity for the professional community associated with GDPUK and creates opportunities for future growth under experienced ownership.”
Tony will continue involvement in GDPUK on a consulting basis.
GDPUK Ltd has worked to ensure an orderly transfer of the intellectual property and wishes Cogora every success in its future development.